Strain Name:

B6.Cg-Tg(BCL2)36Wehi/J

Stock Number:

002321

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names C57BL/6-Tg(BCL2)36Wehi/J    (Changed: 24-JAN-06 )
Type Mutant Strain; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Specieslaboratory mouse
 
Donating InvestigatorDr. Alan Harris,   The Walter & Eliza Hall Inst of Med Res

Appearance
black
Related Genotype: a/a

Description
Expression of the human BCL2 transgene in both T cell and B cell lineages. This transgenic line combines the characteristics of both Tg(BCL2)22Wehi and the Tg(BCL2)25Wehi lines. Hemizygotes show increased numbers of B lymphocytes, Ig-secreting cells and serum Ig, as well as a heightened and prolonged antibody response to immunization. T-cells withstand prolonged culture in the absence of growth factors and are resistant to killing by gamma-radiation, glucocorticoids, ionomycin, PMA and sodium azide but NOT complement, cytotoxic T cells, or Fas ligand. Hemizygotes have a normal total T-cell count and thymic involution rate but show an enhanced response to immunization. These mice serve as a robust source for the production of B-cells, antibodies T-cell lines or hybridomas. Although mice bearing this allele exhibit a mild increase in spontaneous lymphoma and plasmacytoma occurrence (<10% to 18 months) on a (C57BL/6 x SJL)F2 background, on the BALB/c and C57BL/6 backgrounds tumor incidence is insignificant. Hemizygotes on a mixed B6,SJL background (but not on the C57BL/6 background) develop an autoimmune disease characterized by immune complex glomerulonephritis, anti-nuclear antibodies, lymphadenopathy, and myocardial infarction.

Development
The TgN(BCL2)36Wehi transgenic strain was made in the laboratory of Dr. Alan Harris of the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. The transgene construct consisted of the human BCL2 cDNA in association with the Emu immunoglobulin heavy chain enhancer and SV40 promoter. Original background was mix of C57BL/6JWehi and SJL/JWehi. Transgenic mice have been bred to C57BL/6J more than 20 generations.

Control Information

  Control
   Noncarrier
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Related Strains

Strains carrying other alleles of BCL2
002319   B6.Cg-Tg(BCL2)22Wehi/J
002320   B6.Cg-Tg(BCL2)25Wehi/J
002318   C.Cg-Tg(BCL2)22Wehi/J
002427   C3H/He-Tg(LCKprBCL2)36Sjk/J
002971   FVB-Tg(BCL2OVARY)1Ah/J
View Strains carrying other alleles of BCL2     (5 strains)

View Strains carrying other alleles of SV40     (13 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Potential model based on transgenic expression of an ortholog of a human gene that is associated with this disease. Phenotypic similarity to the human disease has not been tested.
B-Cell Cll/Lymphoma 2; BCL2   (BCL2)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Tg(BCL2)36Wehi/?

        B6.Cg-Tg(BCL2)36Wehi/J
  • hematopoietic system phenotype
  • abnormal B cell proliferation
    • anti-CD40 B cell proliferation is increased 3- to 5- fold in the presence of IL-21, which does not occur in wild-type controls   (MGI Ref ID J:90963)
  • decreased B cell apoptosis
    • IL-21 fails to induce apoptosis in LPS-activated B cells as it does in wild-type mice   (MGI Ref ID J:90963)
  • immune system phenotype
  • abnormal B cell proliferation
    • anti-CD40 B cell proliferation is increased 3- to 5- fold in the presence of IL-21, which does not occur in wild-type controls   (MGI Ref ID J:90963)
  • decreased B cell apoptosis
    • IL-21 fails to induce apoptosis in LPS-activated B cells as it does in wild-type mice   (MGI Ref ID J:90963)
  • cellular phenotype
  • decreased B cell apoptosis
    • IL-21 fails to induce apoptosis in LPS-activated B cells as it does in wild-type mice   (MGI Ref ID J:90963)

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Tg(BCL2)36Wehi/0

        involves: C57BL/6JWehi * SJL/JWehi
  • hematopoietic system phenotype
  • abnormal B cell physiology
    • transgenic spleen B cells show prolonged in vitro survival in culture compared to wild-type splenocytes   (MGI Ref ID J:93111)
    • increased immunoglobulin level
      • mice display increased serum immunoglobulin concentrations   (MGI Ref ID J:93111)
  • abnormal T cell physiology
    • transgenic T cells show prolonged in vitro survival in culture compared to wild-type T lymphocytes   (MGI Ref ID J:93111)
  • increased B cell number
    • mutants show an excess of B lymphocytes   (MGI Ref ID J:93111)
  • increased T cell number
    • mutants have an excess of T lymphocytes   (MGI Ref ID J:93111)
  • immune system phenotype
  • abnormal B cell physiology
    • transgenic spleen B cells show prolonged in vitro survival in culture compared to wild-type splenocytes   (MGI Ref ID J:93111)
    • increased immunoglobulin level
      • mice display increased serum immunoglobulin concentrations   (MGI Ref ID J:93111)
  • abnormal T cell physiology
    • transgenic T cells show prolonged in vitro survival in culture compared to wild-type T lymphocytes   (MGI Ref ID J:93111)
  • increased B cell number
    • mutants show an excess of B lymphocytes   (MGI Ref ID J:93111)
  • increased T cell number
    • mutants have an excess of T lymphocytes   (MGI Ref ID J:93111)
  • increased susceptibility to autoimmune disorder
    • some transgenic mice develop a systemic autoimmune-like disease   (MGI Ref ID J:93111)
  • tumorigenesis
  • increased T cell derived lymphoma incidence
    • a few mice develop fatal clonal T cell tumors   (MGI Ref ID J:93111)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Apoptosis Research
Endogenous Regulators

Immunology, Inflammation and Autoimmunity Research
Intracellular Signaling Molecules

Research Tools
Cancer Research
      production of B and T cells, antibodies, and hybridomas
Immunology, Inflammation and Autoimmunity Research
      production of B cells, antibodies T cell lines, and hybridomas

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tg(BCL2)36Wehi
Allele Name transgene insertion 36, Walter and Eliza Hall Institute of Medical Research
Allele Type Transgenic (Inserted expressed sequence)
Common Name(s) Bcl-2-transgenic; E mu-bcl-2-36; Emu-Bcl-2-36;
Mutation Made ByDr. Alan Harris,   The Walter & Eliza Hall Inst of Med Res
Strain of Origin(C57BL/6JWehi x SJL/JWehi)F2
Expressed Gene BCL2, B-cell CLL/lymphoma 2, human
Promoter SV40, E mu enhancer, SV40
General Note

The transgene is expressed in both T cell and B cell lineages.

On a C57BL/6 background hemizygotes show increased numbers of B lymphocytes, Ig-secreting cells and serum Ig, as well as a heightened and prolonged antibody response to immunization. T-cells withstand prolonged culture in the absence of growth factors and are resistant to killing by gamma-radiation, glucocorticoids, ionomycin, PMA, and sodium azide, but not complement, cytotoxic T cells, or Fas ligand. These hemizygotes have a normal total T-cell count and thymic involution rate but show an enhanced response to immunization, and serve as a robust source for the production of B-cells, antibodies T-cell lines or hybridomas.

Although transgenic mice on a (C57BL/6 x SJL)F2 background exhibit a mild increase in spontaneous lymphoma and plasmacytoma occurrence (<10% to 18 months), on the BALB/c and C57BL/6 backgrounds tumor incidence is insignificant. Hemizygotes on a background involving C57BL/6 and SJL (but not on the C57BL/6 background) develop an autoimmune disease characterized by immune complex glomerulonephritis, anti-nuclear antibodies, lymphadenopathy, and myocardial infarction.

Molecular Note The transgene construct consists of the human BCL2 cDNA in association with the Emu immunoglobulin heavy chain enhancer and SV40 promoter. [MGI Ref ID J:93111]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

Tg(BCL2),

MELT



Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Strasser A; Harris AW; Corcoran LM; Cory S. 1994. Bcl-2 expression promotes B- but not T-lymphoid development in scid mice. Nature 368(6470):457-60. [PubMed: 8133891]  [MGI Ref ID J:17426]

Strasser A; Harris AW; Cory S. 1991. bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67(5):889-99. [PubMed: 1959134]  [MGI Ref ID J:69572]

Additional References

Khaled AR; Li WQ; Huang J; Fry TJ; Khaled AS; Mackall CL; Muegge K; Young HA; Durum SK. 2002. Bax deficiency partially corrects interleukin-7 receptor alpha deficiency. Immunity 17(5):561-73. [PubMed: 12433363]  [MGI Ref ID J:93139]

O'Reilly LA; Harris AW; Tarlinton DM; Corcoran LM; Strasser A. 1997. Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. J Immunol 159(5):2301-11. [PubMed: 9278319]  [MGI Ref ID J:93123]

Tan JT; Dudl E; LeRoy E; Murray R; Sprent J; Weinberg KI; Surh CD. 2001. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci U S A 98(15):8732-7. [PubMed: 11447288]  [MGI Ref ID J:93058]

Tg(BCL2)36Wehi related

Bell SE; Vigorito E; McAdam S; Reynolds HM; Caraux A; Colucci F; Turner M. 2004. PLCgamma2 regulates Bcl-2 levels and is required for survival rather than differentiation of marginal zone and follicular B cells. Eur J Immunol 34(8):2237-47. [PubMed: 15259021]  [MGI Ref ID J:91772]

Carrio R; Rolle CE; Malek TR. 2007. Non-redundant role for IL-7R signaling for the survival of CD8(+) memory T cells. Eur J Immunol 37(11):3078-88. [PubMed: 17935075]  [MGI Ref ID J:126334]

Castro I; Yu A; Dee MJ; Malek TR. 2011. The basis of distinctive IL-2- and IL-15-dependent signaling: weak CD122-dependent signaling favors CD8+ T central-memory cell survival but not T effector-memory cell development. J Immunol 187(10):5170-82. [PubMed: 21984699]  [MGI Ref ID J:179645]

Chang CL; Lai YG; Hou MS; Huang PL; Liao NS. 2011. IL-15Ralpha of radiation-resistant cells is necessary and sufficient for thymic invariant NKT cell survival and functional maturation. J Immunol 187(3):1235-42. [PubMed: 21709149]  [MGI Ref ID J:179188]

Cobaleda C; Jochum W; Busslinger M. 2007. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 449(7161):473-7. [PubMed: 17851532]  [MGI Ref ID J:126362]

Cory S; Harris AW; Strasser A. 1994. Insights from transgenic mice regarding the role of bcl-2 in normal and neoplastic lymphoid cells. Philos Trans R Soc Lond B Biol Sci 345(1313):289-95. [PubMed: 7846127]  [MGI Ref ID J:21062]

Egle A; Harris AW; Bath ML; O'Reilly L; Cory S. 2004. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 103(6):2276-83. [PubMed: 14630790]  [MGI Ref ID J:88565]

Fisher IB; Ostrowski M; Muthusamy N. 2012. Role for Ets-2(Thr-72) transcription factor in stage-specific thymocyte development and survival. J Biol Chem 287(8):5199-210. [PubMed: 22128184]  [MGI Ref ID J:182468]

Fry TJ; Christensen BL; Komschlies KL; Gress RE; Mackall CL. 2001. Interleukin-7 restores immunity in athymic T-cell-depleted hosts. Blood 97(6):1525-33. [PubMed: 11238086]  [MGI Ref ID J:93170]

Gordy LE; Bezbradica JS; Flyak AI; Spencer CT; Dunkle A; Sun J; Stanic AK; Boothby MR; He YW; Zhao Z; Van Kaer L; Joyce S. 2011. IL-15 regulates homeostasis and terminal maturation of NKT cells. J Immunol 187(12):6335-45. [PubMed: 22084435]  [MGI Ref ID J:180390]

Grumont RJ; Rourke IJ; O'Reilly LA; Strasser A; Miyake K; Sha W; Gerondakis S. 1998. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med 187(5):663-74. [PubMed: 9480976]  [MGI Ref ID J:46076]

Janas ML; Hodson D; Stamataki Z; Hill S; Welch K; Gambardella L; Trotman LC; Pandolfi PP; Vigorito E; Turner M. 2008. The effect of deleting p110delta on the phenotype and function of PTEN-deficient B cells. J Immunol 180(2):739-46. [PubMed: 18178811]  [MGI Ref ID J:130950]

Ji Y; Resch W; Corbett E; Yamane A; Casellas R; Schatz DG. 2010. The in vivo pattern of binding of RAG1 and RAG2 to antigen receptor loci. Cell 141(3):419-31. [PubMed: 20398922]  [MGI Ref ID J:160370]

Jin H; Carrio R; Yu A; Malek TR. 2004. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 173(1):657-65. [PubMed: 15210829]  [MGI Ref ID J:90963]

Khaled AR; Li WQ; Huang J; Fry TJ; Khaled AS; Mackall CL; Muegge K; Young HA; Durum SK. 2002. Bax deficiency partially corrects interleukin-7 receptor alpha deficiency. Immunity 17(5):561-73. [PubMed: 12433363]  [MGI Ref ID J:93139]

Lai YG; Hou MS; Lo A; Huang ST; Huang YW; Yang-Yen HF; Liao NS. 2013. IL-15 modulates the balance between Bcl-2 and Bim via a Jak3/1-PI3K-Akt-ERK pathway to promote CD8alphaalpha(+) intestinal intraepithelial lymphocyte survival. Eur J Immunol 43(9):2305-16. [PubMed: 23754237]  [MGI Ref ID J:201328]

Li T; Ramirez K; Palacios R. 1996. Distinct patterns of Fas cell surface expression during development of T- or B-lymphocyte lineages in normal, scid, and mutant mice lacking or overexpressing p53, bcl-2, or rag-2 genes. Cell Growth Differ 7(1):107-14. [PubMed: 8788039]  [MGI Ref ID J:31364]

Llorian M; Stamataki Z; Hill S; Turner M; Martensson IL. 2007. The PI3K p110delta is required for down-regulation of RAG expression in immature B cells. J Immunol 178(4):1981-5. [PubMed: 17277100]  [MGI Ref ID J:144002]

Mak TW; Hakem A; McPherson JP; Shehabeldin A; Zablocki E; Migon E; Duncan GS; Bouchard D; Wakeham A; Cheung A; Karaskova J; Sarosi I; Squire J; Marth J; Hakem R. 2000. Brcal required for T cell lineage development but not TCR loci rearrangement. Nat Immunol 1(1):77-82. [PubMed: 10881179]  [MGI Ref ID J:63282]

Maraskovsky E; O'Reilly LA; Teepe M; Corcoran LM; Peschon JJ; Strasser A. 1997. Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1-/- mice. Cell 89(7):1011-9. [PubMed: 9215624]  [MGI Ref ID J:41239]

Mastache EF; Lindroth K; Fernandez C; Gonzalez-Fernandez A. 2006. Somatic hypermutation of Ig genes is affected differently by failures in apoptosis caused by disruption of Fas (lpr mutation) or by overexpression of Bcl-2. Scand J Immunol 63(6):420-9. [PubMed: 16764695]  [MGI Ref ID J:129290]

McPherson JP; Hande MP; Poonepalli A; Lemmers B; Zablocki E; Migon E; Shehabeldin A; Porras A; Karaskova J; Vukovic B; Squire J; Hakem R. 2006. A role for Brca1 in chromosome end maintenance. Hum Mol Genet 15(6):831-8. [PubMed: 16446310]  [MGI Ref ID J:106759]

McPherson JP; Lemmers B; Hirao A; Hakem A; Abraham J; Migon E; Matysiak-Zablocki E; Tamblyn L; Sanchez-Sweatman O; Khokha R; Squire J; Hande MP; Mak TW; Hakem R. 2004. Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev 18(10):1144-53. [PubMed: 15131084]  [MGI Ref ID J:90512]

Meade J; Tybulewicz VL; Turner M. 2004. The tyrosine kinase Syk is required for light chain isotype exclusion but dispensable for the negative selection of B cells. Eur J Immunol 34(4):1102-10. [PubMed: 15048721]  [MGI Ref ID J:131486]

Melichar HJ; Narayan K; Der SD; Hiraoka Y; Gardiol N; Jeannet G; Held W; Chambers CA; Kang J. 2007. Regulation of gammadelta versus alphabeta T lymphocyte differentiation by the transcription factor SOX13. Science 315(5809):230-3. [PubMed: 17218525]  [MGI Ref ID J:117301]

Newton K; Harris AW; Bath ML; Smith KG; Strasser A. 1998. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J 17(3):706-18. [PubMed: 9450996]  [MGI Ref ID J:110608]

Newton K; Strasser A. 2000. Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling. Implications for cancer therapy. J Exp Med 191(1):195-200. [PubMed: 10620618]  [MGI Ref ID J:59250]

Niebuhr B; Kriebitzsch N; Fischer M; Behrens K; Gunther T; Alawi M; Bergholz U; Muller U; Roscher S; Ziegler M; Buchholz F; Grundhoff A; Stocking C. 2013. Runx1 is essential at two stages of early murine B-cell development. Blood 122(3):413-23. [PubMed: 23704093]  [MGI Ref ID J:201181]

O'Reilly LA; Harris AW; Strasser A. 1997. bcl-2 transgene expression promotes survival and reduces proliferation of CD3-CD4-CD8- T cell progenitors. Int Immunol 9(9):1291-301. [PubMed: 9310832]  [MGI Ref ID J:93122]

O'Reilly LA; Harris AW; Tarlinton DM; Corcoran LM; Strasser A. 1997. Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. J Immunol 159(5):2301-11. [PubMed: 9278319]  [MGI Ref ID J:93123]

Owens BM; Hawley TS; Spain LM; Kerkel KA; Hawley RG. 2006. TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage. Br J Haematol 132(2):216-29. [PubMed: 16398656]  [MGI Ref ID J:105116]

Peacock JW; Palmer J; Fink D; Ip S; Pietras EM; Mui AL; Chung SW; Gleave ME; Cox ME; Parsons R; Peter ME; Ong CJ. 2009. PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15. Mol Cell Biol 29(5):1222-34. [PubMed: 19103758]  [MGI Ref ID J:145719]

Priatel JJ; Chen X; Dhanji S; Abraham N; Teh HS. 2006. RasGRP1 transmits prodifferentiation TCR signaling that is crucial for CD4 T cell development. J Immunol 177(3):1470-80. [PubMed: 16849453]  [MGI Ref ID J:137980]

Rietz C; Screpanti V; Brenden N; Bohme J; Fernandez C. 2003. Overexpression of bcl-2 in T cells affects insulitis in the nonobese diabetic mouse. Scand J Immunol 57(4):342-9. [PubMed: 12662297]  [MGI Ref ID J:131889]

Rietz C; Screpanti V; Brenden N; Fernandez C. 2001. Neonatal pattern of V(H) gene utilization in nonobese diabetic mice does not correlate with development of insulitis. Scand J Immunol 54(5):470-6. [PubMed: 11696198]  [MGI Ref ID J:133860]

Rolle CE; Carrio R; Malek TR. 2008. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy. Cancer Res 68(8):2984-92. [PubMed: 18413768]  [MGI Ref ID J:133959]

Shi M; Lin TH; Appell KC; Berg LJ. 2009. Cell cycle progression following naive T cell activation is independent of Jak3/common gamma-chain cytokine signals. J Immunol 183(7):4493-501. [PubMed: 19734221]  [MGI Ref ID J:152788]

Shi M; Lin TH; Appell KC; Berg LJ. 2008. Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity 28(6):763-73. [PubMed: 18549798]  [MGI Ref ID J:137735]

Strasser A; Harris AW; Huang DC; Krammer PH; Cory S. 1995. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 14(24):6136-47. [PubMed: 8557033]  [MGI Ref ID J:31382]

Strasser A; Harris AW; Vaux DL; Webb E; Bath ML; Adams JM; Cory S. 1990. Abnormalities of the immune system induced by dysregulated bcl-2 expression in transgenic mice. Curr Top Microbiol Immunol 166:175-81. [PubMed: 2073796]  [MGI Ref ID J:93111]

Strasser A; Harris AW; von Boehmer H; Cory S. 1994. Positive and negative selection of T cells in T-cell receptor transgenic mice expressing a bcl-2 transgene. Proc Natl Acad Sci U S A 91(4):1376-80. [PubMed: 8108419]  [MGI Ref ID J:16947]

Tan JT; Dudl E; LeRoy E; Murray R; Sprent J; Weinberg KI; Surh CD. 2001. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci U S A 98(15):8732-7. [PubMed: 11447288]  [MGI Ref ID J:93058]

Turchinovich G; Vu TT; Frommer F; Kranich J; Schmid S; Alles M; Loubert JB; Goulet JP; Zimber-Strobl U; Schneider P; Bachl J; Pearson R; Crossley M; Agenes F; Kirberg J. 2011. Programming of marginal zone B-cell fate by basic Kruppel-like factor (BKLF/KLF3). Blood 117(14):3780-92. [PubMed: 21297003]  [MGI Ref ID J:172846]

Wilkinson B; Kaye J. 2001. Requirement for sustained MAPK signaling in both CD4 and CD8 lineage commitment: a threshold model. Cell Immunol 211(2):86-95. [PubMed: 11591112]  [MGI Ref ID J:115623]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryThis strain is maintained by mating hemizygous mice with C57BL/6J mice or wildtype siblings. Expected coat color from breeding:Black

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2525.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3283.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Control Information

  Control
   Noncarrier
   000664 C57BL/6J
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.6)